search
Back to results

Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

Primary Purpose

Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia

Status
Withdrawn
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Pacritinib
Decitabine
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Myelomonocytic Leukemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Confirmed diagnosis of:

    • Primary MF or post-PV/ET MF classified as high risk, intermediate-2 risk, or intermediate-1 risk who are unresponsive or unable to receive current therapy which may or may not include ruxolitinib OR
    • MPN/MDS Syndrome (chronic myelomonocytic leukemia [CMML], juvenile myelomonocytic leukemia [JMML], atypical chronic myeloid leukemia [aCML], or MDS/MPN unclassifiable)
  • ECOG 0-3
  • Required laboratory values:

    • Neutrophil count of ≥ 0.5 x 109/L
    • Bone marrow blood blast count < 20%
    • AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days)
    • Total creatinine < 2.5mg/dL
    • Total bilirubin ≤ 2.0 x ULN
  • Age ≥ 18 years old at enrollment.
  • If female, must be:

    • postmenopausal for at least 1 year before the screening visit OR
    • surgically sterile OR
    • agreeable to practicing 2 effective methods of contraception prior to study entry, for the duration of study participation, and for 30 days after the last dose of study treatment.
  • Able to swallow pills.
  • If a sexually active heterosexual male, must be agreeable to practicing 2 effective methods of contraception prior to study entry, for the duration of study participation, and for 30 days after the last dose of study treatment.
  • Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

  • Prior treatment with more than two JAK2 inhibitors or with pacritinib
  • Known positive status for human immunodeficiency virus (HIV)
  • Chronic, active, or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrier
  • Use of chemotherapy, biologic therapy, radiation therapy, erythropoietin or related erythropoiesis stimulating agents, or investigational therapy within 2 weeks of the first dose of study drug
  • History of allogeneic stem cell transplant or transplant eligible
  • Currently receiving any other investigational agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the study
  • Ongoing gastrointestinal medical condition such as Crohn's disease, inflammatory bowel disease, chronic diarrhea, or chronic constipation that could interfere with absorption of oral medication
  • Active bleeding that requires hospitalization during the screening period
  • Cardiovascular disease, including recent history of or currently clinically symptomatic and uncontrolled congestive heart failure, arrhythmia, angina, QTc prolongation or other QTc risk factors, myocardial infarction. Patients with CTCAE grade 2 cardiac arrhythmias may be considered for inclusion if the arrhythmias are stable, asymptomatic, and unlikely to affect patient safety. Patients will e excluded if they have ongoing cardiac dysrhythmias of CTCAE grade ≥ 3, corrected QT interval (QTc) prolongation > 450 ms, or other factors that increase the risk for QT interval prolongation (e.g., heart failure, hypokalemia [defined as serum potassium < 3.0 mEq/L that is persistent and refractory to correction], or family history of long QT interval syndrome).
  • Other malignancy requiring active treatment at time of study entry
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or serious medical or psychiatric illness/social situations that would limit compliance with study requirements.
  • Life expectancy < 6 months
  • Pregnant and/or breastfeeding. Patient must have a negative pregnancy test within 14 days of study entry.
  • Receiving treatment with any potent CYP3A4 inhibitors within 7 days of the first dose of study drug
  • Patients with MF who are eligible for enrollment in the pacritinib "PERSIST-2" study at WUSM (NCT02055781) HRPO 201406075.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Arm 1: Pacritinib and Decitabine

    Arm Description

    Patients will receive one cycle of single agent pacritinib. Patients who tolerate single agent pacritinib will then receive up to 11 cycles of pacritinib and decitabine combination therapy. Patients who do not tolerate single agent pacritinib (require dose interruption for more than 7 days before Cycle 2 Day 1) will be considered non-evaluable and replaced. Pacritinib will be administered orally at a dose of 200 mg twice daily continuously for Days 1 through 28 of a 28-day cycle. Decitabine will be administered as a subcutaneous injection in clinic on Days 1, 5, 8, 12, 15, 19, 22, and 26 of a 28-day cycle. Patients may continue treatment for up to 12 cycles.

    Outcomes

    Primary Outcome Measures

    Safety of regimen as measured by adverse events
    The descriptions and grading for adverse events are found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

    Secondary Outcome Measures

    Rate of objective response as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) consensus
    Objective response is defined as CR (complete remission/response) + PR (partial remission/response) + CI (clinical improvement).
    Rate of hematologic response
    -Anemia response Anemia response is only applicable for patients with baseline hemoglobin level less than 10g/dL for 8 weeks or more and requires: *≥2 g/dL increase in hemoglobin level *becoming transfusion-independent (no RBC transfusions in past 1 month) -Platelet response Platelet response is only applicable for patients with a baseline platelet count of less than 50 x 10^9/L for 8 weeks or more, and requires: 100% increase in platelet count AND An absolute platelet count of at least 50 x 10^9/L
    Rate of symptom response as measured by the total symptom score (TSS)
    A ≥50% reduction in the myeloproliferative neoplasm symptom assessment total symptom score
    Rate of spleen response
    A baseline splenomegaly that is palpable at 5-10 cm below the left costal margin becomes not palpable OR A baseline splenomegaly that is palpable > 10 cm below the left costal margin decreases by ≥50% OR A baseline splenomegaly that is palpable < 5 cm below the left costal margin is not eligible for spleen response OR MRI or CT shows ≥35% spleen volume reduction

    Full Information

    First Posted
    September 29, 2015
    Last Updated
    May 3, 2017
    Sponsor
    Washington University School of Medicine
    Collaborators
    CTI BioPharma
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02564536
    Brief Title
    Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
    Official Title
    A Pilot Study of Pacritinib in Combination With Low Dose Decitabine in Patients With Intermediate-High Risk Myelofibrosis or MPN/MDS Syndromes
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2017
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Lack of funding following full FDA clinical hold
    Study Start Date
    June 2017 (Anticipated)
    Primary Completion Date
    June 30, 2020 (Anticipated)
    Study Completion Date
    June 30, 2020 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Washington University School of Medicine
    Collaborators
    CTI BioPharma

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    For the first 28 day cycle, all patients will be treated with single agent pacritinib at 200 mg twice daily. The investigators chose this starting dose based on the previous three phase I studies of pacritinib as a single agent which showed that the maximum tolerated dose (MTD) to be 500 mg, and subsequently, the dose of 400 mg daily was recommended for the phase II studies. Recently, the results of the phase III PERSIST-1 trial comparing pacritinib to best available therapy (BAT) in patients with MF was reported at the 2015 American Society of Clinical Oncology (ASCO) annual meeting. Pacritinib was found to be significantly more effective than BAT at reducing spleen volume at 24 weeks of therapy and improving constitutional symptoms. Low dose decitabine has demonstrated depletion of DNMT1 in normal hematopoietic stem cells (HSC) without cytotoxicity and subcutaneous (SC) instead of intravenous (IV) administration may avoid high peak levels that can cause apoptosis. Furthermore, the low toxicity associated with low dose decitabine would allow for more frequent (1 to 3 times weekly) administration of the drug which would catch more cells in S-phase via greater exposure time. Based on these findings, a starting dose of decitabine 5 mg/m2 SC twice weekly should be well tolerated and effective in patients with MF and MPN/MDS syndromes when combined with pacritinib 400 mg daily.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes, Myelofibrosis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Arm 1: Pacritinib and Decitabine
    Arm Type
    Experimental
    Arm Description
    Patients will receive one cycle of single agent pacritinib. Patients who tolerate single agent pacritinib will then receive up to 11 cycles of pacritinib and decitabine combination therapy. Patients who do not tolerate single agent pacritinib (require dose interruption for more than 7 days before Cycle 2 Day 1) will be considered non-evaluable and replaced. Pacritinib will be administered orally at a dose of 200 mg twice daily continuously for Days 1 through 28 of a 28-day cycle. Decitabine will be administered as a subcutaneous injection in clinic on Days 1, 5, 8, 12, 15, 19, 22, and 26 of a 28-day cycle. Patients may continue treatment for up to 12 cycles.
    Intervention Type
    Drug
    Intervention Name(s)
    Pacritinib
    Intervention Description
    -Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.
    Intervention Type
    Drug
    Intervention Name(s)
    Decitabine
    Intervention Description
    -From commercial stock
    Primary Outcome Measure Information:
    Title
    Safety of regimen as measured by adverse events
    Description
    The descriptions and grading for adverse events are found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
    Time Frame
    30 days after completion of treatment (up to 1 year)
    Secondary Outcome Measure Information:
    Title
    Rate of objective response as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) consensus
    Description
    Objective response is defined as CR (complete remission/response) + PR (partial remission/response) + CI (clinical improvement).
    Time Frame
    End of treatment (up to 48 weeks)
    Title
    Rate of hematologic response
    Description
    -Anemia response Anemia response is only applicable for patients with baseline hemoglobin level less than 10g/dL for 8 weeks or more and requires: *≥2 g/dL increase in hemoglobin level *becoming transfusion-independent (no RBC transfusions in past 1 month) -Platelet response Platelet response is only applicable for patients with a baseline platelet count of less than 50 x 10^9/L for 8 weeks or more, and requires: 100% increase in platelet count AND An absolute platelet count of at least 50 x 10^9/L
    Time Frame
    End of treatment (up to 48 weeks)
    Title
    Rate of symptom response as measured by the total symptom score (TSS)
    Description
    A ≥50% reduction in the myeloproliferative neoplasm symptom assessment total symptom score
    Time Frame
    End of treatment (up to 48 weeks)
    Title
    Rate of spleen response
    Description
    A baseline splenomegaly that is palpable at 5-10 cm below the left costal margin becomes not palpable OR A baseline splenomegaly that is palpable > 10 cm below the left costal margin decreases by ≥50% OR A baseline splenomegaly that is palpable < 5 cm below the left costal margin is not eligible for spleen response OR MRI or CT shows ≥35% spleen volume reduction
    Time Frame
    End of treatment (up to 48 weeks)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Confirmed diagnosis of: Primary MF or post-PV/ET MF classified as high risk, intermediate-2 risk, or intermediate-1 risk who are unresponsive or unable to receive current therapy which may or may not include ruxolitinib OR MPN/MDS Syndrome (chronic myelomonocytic leukemia [CMML], juvenile myelomonocytic leukemia [JMML], atypical chronic myeloid leukemia [aCML], or MDS/MPN unclassifiable) ECOG 0-3 Required laboratory values: Neutrophil count of ≥ 0.5 x 109/L Bone marrow blood blast count < 20% AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days) Total creatinine < 2.5mg/dL Total bilirubin ≤ 2.0 x ULN Age ≥ 18 years old at enrollment. If female, must be: postmenopausal for at least 1 year before the screening visit OR surgically sterile OR agreeable to practicing 2 effective methods of contraception prior to study entry, for the duration of study participation, and for 30 days after the last dose of study treatment. Able to swallow pills. If a sexually active heterosexual male, must be agreeable to practicing 2 effective methods of contraception prior to study entry, for the duration of study participation, and for 30 days after the last dose of study treatment. Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable). Exclusion Criteria: Prior treatment with more than two JAK2 inhibitors or with pacritinib Known positive status for human immunodeficiency virus (HIV) Chronic, active, or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrier Use of chemotherapy, biologic therapy, radiation therapy, erythropoietin or related erythropoiesis stimulating agents, or investigational therapy within 2 weeks of the first dose of study drug History of allogeneic stem cell transplant or transplant eligible Currently receiving any other investigational agents History of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the study Ongoing gastrointestinal medical condition such as Crohn's disease, inflammatory bowel disease, chronic diarrhea, or chronic constipation that could interfere with absorption of oral medication Active bleeding that requires hospitalization during the screening period Cardiovascular disease, including recent history of or currently clinically symptomatic and uncontrolled congestive heart failure, arrhythmia, angina, QTc prolongation or other QTc risk factors, myocardial infarction. Patients with CTCAE grade 2 cardiac arrhythmias may be considered for inclusion if the arrhythmias are stable, asymptomatic, and unlikely to affect patient safety. Patients will e excluded if they have ongoing cardiac dysrhythmias of CTCAE grade ≥ 3, corrected QT interval (QTc) prolongation > 450 ms, or other factors that increase the risk for QT interval prolongation (e.g., heart failure, hypokalemia [defined as serum potassium < 3.0 mEq/L that is persistent and refractory to correction], or family history of long QT interval syndrome). Other malignancy requiring active treatment at time of study entry Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or serious medical or psychiatric illness/social situations that would limit compliance with study requirements. Life expectancy < 6 months Pregnant and/or breastfeeding. Patient must have a negative pregnancy test within 14 days of study entry. Receiving treatment with any potent CYP3A4 inhibitors within 7 days of the first dose of study drug Patients with MF who are eligible for enrollment in the pacritinib "PERSIST-2" study at WUSM (NCT02055781) HRPO 201406075.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Camille Abboud, M.D.
    Organizational Affiliation
    Washington University School of Medicine
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Links:
    URL
    http://www.siteman.wustl.edu
    Description
    Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

    Learn more about this trial

    Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

    We'll reach out to this number within 24 hrs